ABSTRACT
Biomarkers, when compared with a true endpoint such as survival, can often be measured earlier, easily, and more frequently, are less subject to competing risks, and less confounded. The utilization of biomarker will lead to a better target population with a larger effect size, a smaller sample-size required, and faster decision-making.
With the advancement of proteomic, genomic, and genetic technologies, personalized medicine with the right drug for the right patient has become possible.
